(Q37783623)

23 August 2017

title

Early oncology clinical trial design in the era of molecular-targeted agents (English)

1 reference

23 August 2017

Early Oncology Clinical Trial Design in the Era of Molecular-Targeted Agents (English)

1 reference

2 July 2024

0 references

3

Johann S. de Bono

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20799878

2 July 2024

author name string

Andre T. Brunetto

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20799878

2 July 2024

Rebecca S. Kristeleit

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20799878

2 July 2024

language of work or name

English

0 references

publication date

1 August 2010

1 reference

full work available at URL

23 August 2017

http://www.futuremedicine.com/doi/abs/10.2217/fon.10.92

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20799878

https://www.tandfonline.com/doi/pdf/10.2217/fon.10.92

2 July 2024

1 reference

2 July 2024

1 reference

23 August 2017

volume

6

1 reference

23 August 2017

issue

8

1 reference

23 August 2017

page(s)

1339-1352

1 reference

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

23 August 2017

cites work

1 reference

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

21 January 2018

1 reference

Phase I dose-finding and pharmacokinetic study of docetaxel and vinorelbine as first-line chemotherapy for metastatic breast cancer

21 January 2018

1 reference

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

Is cell death a critical end point for anticancer therapies or is cytostasis sufficient?

21 January 2018

1 reference

Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development?

21 January 2018

1 reference

Translation of innovative designs into phase I trials.

21 January 2018

1 reference

Design and analysis of phase I clinical trials

21 January 2018

1 reference

Bayesian design and analysis of two x two factorial clinical trials.

21 January 2018

1 reference

A phase I study to determine the effect of tamoxifen on the pharmacokinetics of a single 250 mg oral dose of gefitinib (IRESSA) in healthy male volunteers

21 January 2018

1 reference

Toxicity and response criteria of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice

21 January 2018

1 reference

Pharmacologically guided phase I clinical trials based upon preclinical drug development

21 January 2018

1 reference

Continual reassessment method: a practical design for phase 1 clinical trials in cancer.

21 January 2018

1 reference

Cancer phase I clinical trials: efficient dose escalation with overdose control.

21 January 2018

1 reference

Challenges and pitfalls of combining targeted agents in phase I studies

21 January 2018

1 reference

Targeting targeted agents: open issues for clinical trial design

21 January 2018

1 reference

Survival prediction in terminally ill cancer patients by clinical estimates, laboratory tests, and self-rated anxiety and depression

21 January 2018

1 reference

Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience

21 January 2018

1 reference

Prospective validation of a prognostic score to improve patient selection for oncology phase I trials

21 January 2018

1 reference

Survival of patients in a Phase 1 Clinic: the M. D. Anderson Cancer Center experience

21 January 2018

1 reference

Treatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave Roussy.

21 January 2018

1 reference

Patient motivations surrounding participation in phase I and phase II clinical trials of cancer chemotherapy

21 January 2018

1 reference

The ethical dilemma of phase I clinical trials.

21 January 2018

1 reference

Perceptions of patients and physicians regarding phase I cancer clinical trials: implications for physician-patient communication.

21 January 2018

1 reference

Do specialist palliative care teams improve outcomes for cancer patients? A systematic literature review.

21 January 2018

1 reference

Palliative care: views of patients and their families

21 January 2018

1 reference

Clinical trial design for target-based therapy

21 January 2018

1 reference

Development of target-based antineoplastic agents

21 January 2018

1 reference

Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter?

21 January 2018

1 reference

Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development

21 January 2018

1 reference

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas

21 January 2018

1 reference

Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer

21 January 2018

1 reference

Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levels

21 January 2018

1 reference

Imaging tumor vascular heterogeneity and angiogenesis using dynamic contrast-enhanced magnetic resonance imaging.

21 January 2018

1 reference

Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone.

21 January 2018

1 reference

Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors

21 January 2018

1 reference

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

21 January 2018

1 reference

Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition

21 January 2018

1 reference

Impact and perceptions of mandatory tumor biopsies for correlative studies in clinical trials of novel anticancer agents

21 January 2018

1 reference

A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy

21 January 2018

1 reference

Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer a

21 January 2018

1 reference

Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors

21 January 2018

1 reference

MRI-measured water mobility increases in response to chemotherapy via multiple cell-death mechanisms

21 January 2018

1 reference

Diffusion-weighted magnetic resonance imaging for monitoring diffusion changes in rectal carcinoma during combined, preoperative chemoradiation: preliminary results of a prospective study

21 January 2018

1 reference

Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response

21 January 2018

1 reference

Changes in water mobility measured by diffusion MRI predict response of metastatic breast cancer to chemotherapy

21 January 2018

1 reference

Reproducibility and changes in the apparent diffusion coefficients of solid tumours treated with combretastatin A4 phosphate and bevacizumab in a two-centre phase I clinical trial.

21 January 2018

1 reference

Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography

21 January 2018

1 reference

Overexpression of Glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma.

21 January 2018

1 reference

Evaluation of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography for gastric cancer

21 January 2018

1 reference

18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec).

21 January 2018

1 reference

FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology

21 January 2018

1 reference

Predictive and prognostic value of FDG-PET in nonsmall-cell lung cancer: a systematic review.

21 January 2018

1 reference

The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations.

21 January 2018

1 reference

Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases

21 January 2018

1 reference

Circulating tumor cells, disease progression, and survival in metastatic breast cancer

21 January 2018

1 reference

Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer

21 January 2018

1 reference

Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer

21 January 2018

1 reference

Trends in the use and role of biomarkers in phase I oncology trials

21 January 2018

1 reference

Biomarkers in cancer staging, prognosis and treatment selection

21 January 2018

1 reference

Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies

21 January 2018

1 reference

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

21 January 2018

1 reference

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

21 January 2018

1 reference

Sporadic epithelial ovarian cancer: clinical relevance of BRCA1 inhibition in the DNA damage and repair pathway

21 January 2018

1 reference

A systems approach to analysis of molecular complexity in breast cancer

21 January 2018

1 reference

Potential Applications for Circulating Tumor Cells Expressing the Insulin-Like Growth Factor-I Receptor

21 January 2018

1 reference

Are we taking without giving in return? The ethics of research-related biopsies and the benefits of clinical trial participation

21 January 2018

1 reference

High-throughput oncogene mutation profiling in human cancer

21 January 2018

1 reference

PERSPECTIVES IN CANCER CHEMOTHERAPY: THERAPEUTIC DESIGN

21 January 2018

4

1 reference

Clinical pharmacokinetics of carboplatin

2 July 2024

6

1 reference

In vivo and in vitro pharmacokinetic differences between four structurally closely related anthracyclines in hematopoietic cell subtypes in humans.

2 July 2024

7

1 reference

New paradigm in dose-finding trials: patient-specific dosing and beyond phase I

2 July 2024

22

1 reference

Clinical trial designs for cytostatic agents: are new approaches needed?

2 July 2024

23

1 reference

Dose selection in phase I studies: why we should always go for the top

2 July 2024

25

1 reference

Dose escalation trial designs based on a molecularly targeted endpoint

2 July 2024

27

1 reference

Multivariable analysis of prognostic factors for toxicity and survival for patients enrolled in phase I clinical trials

2 July 2024

32

1 reference

Prognostic factors among cancer patients with good performance status screened for phase I trials

2 July 2024

33

1 reference

Impact of quality of life on patient expectations regarding phase I clinical trials.

2 July 2024

36

1 reference

Perceptions of cancer patients and their physicians involved in phase I trials

2 July 2024

38

1 reference

The evolution of palliative care

2 July 2024

40

1 reference

Multi-institutional phase I trials of anticancer agents

2 July 2024

45

1 reference

Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients.

2 July 2024

59

1 reference

Using biomarkers in drug development.

2 July 2024

60

1 reference

2 July 2024

Identifiers

DOI

10.2217/FON.10.92

1 reference

23 August 2017

1 reference